Ask a pharmacist what a compounding pharmacy makes and you will hear anything from “huge margins” to “it barely pays for itself.” Both are true, depending on what is being compounded, who is paying, how it is priced, and how much commercial dispensing sits alongside it.
This article draws on the dispensing records of Canadian compounding pharmacies we have worked with, analysed line by line, to show what each type of compound actually earns. They range from recently opened compounding led pharmacies with a sterile suite to established non sterile specialty compounders. Figures are rounded or given as ranges, and details from more than one pharmacy are combined, so no single business can be identified.
Margin by product type
In a compounding led pharmacy with a sterile suite, over its first year of operation, the pattern looked like this:
| Product type | Gross margin | Gross profit per fill | Share of total gross profit |
|---|---|---|---|
| Topical pain creams (multi ingredient) | roughly 50% to 60% | often $100 to $170 | the largest single share, up to two fifths |
| Hormone capsules and creams | around 80% | varies by product | under a fifth |
| Progesterone sustained release capsules | above 90% | around $100 | within hormones |
| Erectile dysfunction compounds | 85% to 90% | around $100 or more | under a tenth |
| Testosterone injections | around 80% | often above $200 | under a tenth |
| Oral liquids and paediatric suspensions | around 70% | varies | under a tenth |
| Commercial prescriptions | well under 20% | $40 to $75 on high cost drugs | small |
In established non sterile compounders, the ranges are similar:
| Product type | Gross margin |
|---|---|
| Patient compounds with a compounding fee | 70% to 95% |
| Dermatology bases and combinations | often above 80% |
| Bulk compounds sold to other pharmacies, no fee | 30% to 65% |
| Commercial prescriptions | lower, with drug cost often well over half of the claim |
A few patterns hold across all of them.
Topical pain creams carry the business. They have the lowest margin among compounds, because a five or six ingredient cream uses a lot of active ingredient. But they have the highest volume and a high ticket, so they produce the most gross profit. In the pharmacies we have analysed they are commonly the largest single source of compound gross profit.
Simple capsules have the best margin. A hormone or low dose naltrexone capsule uses very little active ingredient. Almost all of the price is the compounding fee. These can run above 90 percent, but at a lower dollar amount per fill.
Injections have the best gross profit per fill. Sterile preparations take the most skill and the most facility, and they are priced accordingly. A testosterone injection can earn more than twice the gross profit of the average compound. That is the economic case for a sterile suite, as long as the demand is there to use it.
B2B work has lower margins and steadier volume. When a pharmacy compounds for other pharmacies, it usually sells at a price per gram or per unit with no patient compounding fee, because the ordering pharmacy charges the patient its own fee. Margins are lower, but the orders recur and do not depend on the compounding pharmacy’s own prescribers.
What is actually in a compounding book
The marketing for compounding focuses on hormones and men’s health. The dispensing data tells a different story, and it differs from one pharmacy to the next.
In established non sterile compounders, topical pain and dermatology together often make up most of compound revenue, followed by paediatric and oral suspensions, hair loss, and smaller lines such as fissure ointments and low dose naltrexone. Hormones and sexual health can be a much smaller share than the marketing would suggest, and some pharmacies do no weight loss compounding at all.
In newer pharmacies whose prescriber base includes clinics focused on hormones and men’s health, those lines can be a third or more of gross profit.
The lesson for an owner or a buyer: a compounding pharmacy’s book is a mirror of its prescribers. Two pharmacies of the same size can have completely different margin profiles because different doctors, nurse practitioners and naturopaths send them work.
Why the blended margin falls as sales grow
In a typical start up, the compound margin can hold between 60 and 70 percent month after month while the overall margin falls from the mid 50s to the high 40s over the first year.
The reason is commercial dispensing. Commercial prescriptions can grow from about a tenth of revenue to about a third within months, driven by products such as intravenous iron infusions and GLP 1 pens. A single iron infusion can bring in several hundred dollars of revenue but only a modest gross profit, and a GLP 1 pen often earns $40 to $75. That is good business in dollars, but it pulls the percentage down.
This matters in three places. In management, because an owner watching only the blended margin will think the pharmacy is getting less efficient when it is not. In financing, because a lender reading the statements needs the split to understand the trend. And in a sale, because a buyer will value compound gross profit and commercial gross profit differently. Report them separately from day one.
Pricing: where most compounding pharmacies leave money behind
The single biggest margin lever in a compounding pharmacy is not what you compound. It is how you price it.
A compound price has three parts: the ingredient cost, a markup on that cost, and a compounding fee for the time and skill involved. Many pharmacies set the fee once when they open and never revisit it. Some charge the same fee for a two minute capsule fill and a forty minute multi ingredient cream.
We have seen a pharmacy move from a single, long unchanged fee to tiered fees based on complexity, review its bulk prices for B2B customers, and adjust its dispensing fee on commercial prescriptions at the same time. With volume roughly flat afterwards, compound gross profit rose substantially.
That is a strong result, but the direction is common. When we review a compounding pharmacy’s pricing we usually find some combination of:
- one flat fee regardless of complexity;
- formulas costed years ago and never updated, now near zero margin;
- batch preparations logged at zero cost or zero price, which distorts the reports;
- B2B prices set by negotiation and never reviewed;
- no allowance for plan caps, so the posted price is not what is collected.
A pricing review is often the fastest way to improve a compounding pharmacy’s profit, and it costs nothing to build.
Payer mix and write downs
Compounding is often described as a cash business. It is less so than people think.
In the pharmacies we have analysed, somewhere between a third and a half of revenue was paid entirely by patients. The rest had a private insurer or public plan on the claim. Cash claims tend to earn a higher margin with no write downs. Insured claims have a lower margin, and plan write downs, the difference between what the pharmacy billed and what the plans accepted, can run at several percent of revenue once insured volume builds.
Reimbursement for compounds varies by plan and province. Some plans cap the compounding fee or the time they will pay for, and some decline certain preparations. A plan that relies on insurers paying full price for every compound will overstate revenue.
The cash share has value of its own. It is revenue that no formulary change can take away, and buyers treat it as a sign of a loyal patient base.
Concentration: the margin risk nobody prices
High margins are only worth what they are likely to be next year. In most compounding pharmacies we see, a small number of formulas and prescribers carry a large share of profit.
It is common for one formula to be a meaningful share of all sales, for the top five formulas to produce a large part of gross profit, and for one or two prescribers to account for a large share of dispensing dollars.
Neither is unusual for a compounding pharmacy, and neither is a reason not to own one. But both should be measured, monitored and, before a sale, explained. Our article on what a pharmacy attached to a medical clinic is worth covers how buyers handle prescriber concentration.
Regulatory limits on margin
Some of the highest margins in compounding have come from products that regulators later restricted. Health Canada’s position of 2 June 2025 treats most compounding of semaglutide as unauthorized, and generic semaglutide products began receiving approval in 2026. A business plan or valuation built on compounded GLP 1 revenue would not survive diligence today.
The broader rule is Health Canada’s policy that separates compounding, which is patient specific and done under a provincial pharmacy licence, from manufacturing, which needs a federal licence. Margins earned on the right side of that line are durable. Margins earned by drifting across it are not.
Read your own reports carefully
Before trusting any margin figure, check how your dispensing system counts. Reversals, usually a claim cancelled and rebilled when the plan changes, can be a sizeable share of rows, so counting rows as prescriptions overstates volume. Batch preparations, large capsule lots made ahead for several patients, are sometimes logged with cost and no revenue, which pulls the reported margin down. And two standard reports from the same system can give noticeably different compound revenue figures because they define a compound differently.
None of this is unusual. But a buyer, a lender or your own accountant will find it, so set up your categories, batch logging and reports properly from the start, and reconcile them at year end.
What to do with this
If you own a compounding pharmacy, split your reporting into compounds and commercial, track margin by category and by formula, and review your fee schedule and formula costing every year. If you are planning one, build your business plan on category margins rather than a single blended figure, and see our article on the first year of a compounding pharmacy for how those margins showed up month by month.
We are pharmacists who have built, run and sold pharmacies, and we have analysed compounding books line by line for owners, buyers and new builds. For a pricing review, a business plan, or help planning a compounding pharmacy, see our guide to building a pharmacy in Canada or contact us to book a consultation.